A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer

Trial Profile

A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to a TRACON Pharmaceuticals media release, the complete enrollment of approximately 18 patients is expected by the end of 2018.
    • 18 Oct 2017 Results (n=9) assessing safety,tolerability and to determine recommended phase 2 dose, presented at the 18th World Conference on Lung Cancer.
    • 15 Oct 2017 According to a TRACON Pharmaceuticals media release, data was presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top